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Cerenkov radiation (CR) has been used in various biological research fields, which has
aroused lots of attention in recent years. Combining optical imaging instruments and most
of nuclear medicine imaging or radiotherapy probes, the CR was developed as a new
imaging modality for biology studies, called Cerenkov luminescence imaging (CLI). On
the other hand, it was novelly used as an internal excitation source to activate some
fluorophores for energy transfer imaging. However, it also has some shortages such as
relatively weak luminescence intensity and low penetration in tissue. Thus some scientific
groups demonstrated to optimize the CLI and demonstrated it to three-dimension
tomography. In this article, we elaborate on its principle, history, and applications and
discuss a number of directions for technical improvements. Then concluded some
advantages and shortages of CR and discuss some prospects of it.
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INTRODUCTION
Cerenkov radiation (CR) is commonly used in experimental
physics to detect small amounts and low concentrations of
radioactive atoms. Recently, its applications in biological research
have been of great interest. Since 2009, Cerenkov luminescence
imaging (CLI), which combines radionuclide labeled probes and
optical imaging (OI) instruments, has been actively explored
by many research groups. Several recent papers have reviewed
the various applications of this new imaging technology [1–6].
Except for CLI, the applications of CR for other purposes, such
as radionuclide detection, radiotherapy dose calibration and flu-
orophores excitation, have also been demonstrated by several
groups. CLI was recently also reported for human thyroid imag-
ing, which represents its first use in clinic.
In this review, we will introduce the Cerenkov luminescence
(CL) technique, including the basic principle and history of CL.
Next, we will discuss some of its basic applications in the past
half-century. We will then focus on the preclinical CL studies and
the first human use of CLI. In the third and fourth section, we
will review some technologies for optimizing CLI and Cerenkov
luminescence tomography (CLT). In the last two sections, we will
discuss the shortcomings of CLI and some potential directions for
technical improvements and biomedical applications.
THE HISTORY AND BASIC THEORY AND FEATURES OF CR
In 1934, S. I. Vavilov and Pavel Alekseyevich Cerenkov published
two reports independently, indicating that high-speed Compton
electrons, which were produced by the Compton effect of gamma
rays, caused the luminescence of solutions. Subsequently, by fur-
ther experiments, it was established that the light was produced
by charged particles that moved uniformly in the substance at a
speed exceeding the phase velocity of light in this medium. This
theory was built by Ilya Frank and Igor Tamm in 1936 with the
discovery of asymmetry. However, it seems contradictory to the
theory of relativity that material bodies are unable to move at
the speed of light, much less to exceed it. However, this can be
explained by the difference between the speed of the propagation
of light waves in a substance and in a vacuum (c), which is caused
by the power of the refractive index (n) of the medium. When
visible light is transferring in a medium with n > 1, the speed of
the propagation of the light waves in the medium is equal to c/n,
and consequently, this will be smaller than the velocity of light in
a vacuum. For example, taking the refractive index of water to be
approximately 1.33, the speed of light in water is approximately
0.75 c. On the other hand, the velocity of the β particles emitted
from radioactive substances is very near to the velocity of light
(c). For 18F, the energy of the positron is 635 keV, and according
to Einstein’s famous relativity equation (Equation 1), the speed of
the positron is approximately 0.895 c.
E = mc2
⎛
⎝ 1√
1 − v2
c2
− 1
⎞
⎠ (1)
Thus, according to this principle, these particles can possess a
speed that is greater than that of light in this substance (0.75 c).
According to the CR theory, luminescence can only be pro-
duced when βn > 1, where β is the ratio v/c (v is the velocity of
charged particle and c is the light speed in vacuum). As such, the
threshold energy of the charged particles for CR production in
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a medium is relative to the refractive index of the medium, this
correlation was figured out by Mitchell et al. [4]. We plotted the
threshold energy of charged particles as a function of the refrac-
tive index of medium according to the Equation (1) (Figure 1A).
For example, the threshold energy of β particles in water (n =
1.33) is 0.261MeV, while in tissue, assuming a refractive index of
1.4, it is 0.219MeV.
The equation formulated by J.V. Jelley to calculate the number
of photons (N) generated by an electron within a spectral region
from λ1 to λ2 along an arbitrary distance L is [7]:
N = 2παL
(
1
λ2
− 1
λ1
)
·
(
1 − 1
β2n2
)
, (2)
where α is the fine structure constant e2/hc equal to 1/137.
In 2010, Spinelli et al. proposed the following equation based
on Equation (2) to calculate the total number of light photons,
Ntot, generated by a positron along an arbitrary distance that is
much smaller than the particle range, L. [8–10]:
Ntot =
∫ Emax
Emin
gF (Z, E) E2(Emax − E)2 1
c
2παL
1
λ
√
1 − m
2
0c
4
E2
×
⎛
⎜⎝1 − 1(
1 − m20c4
E2
)
n2
⎞
⎟⎠ dE. (3)
FIGURE 1 | Basic physics of CL. (A) Threshold of charged particles energy
for CL production as a function of refractive index, n. (B) The CL intensity
distribution as a function of the charged particles energy. (C) Average CL
intensity produced by various radionuclides. It showed the CL intensity of
all tested radionuclides except for 99mTc were highly sensitive to the
radioactivity. (D) The CL spectra of various radionuclides. Similar spectra
were observed from different radionuclides as the signals of CL will
decrease with the increasing of wavelength (C,D were adapted with the
permission of Liu et al. [13]).
Accordingly, the Cerenkov luminescence spectrum is equal to
the following:
dNtot
dλ
= αtot L
λ2
∫ Emax
Emin
F (Z, E) E2(Emax − E)2
√
1 − m
2
0c
4
E2
×
⎛
⎜⎝1 − 1(
1 − m20c4
E2
)
n2
⎞
⎟⎠ dE, (4)
where λ is the wavelength of the CL, E is the minimum positron
energy, Emax is the maximum positron energy, Emin is the min-
imum energy of the particle such that Cerenkov emission takes
place, p is the particle momentum, g is a constant, αtot is given by
the following formula:
αtot = 2πα g
c
(5)
and F(Z, E) is the Fermi function given by the following formula:
F (Z, E) = −2παZE
p
(
1 − e 2παZEp
)−1
(6)
From the equations above, the CL intensity and distribution cor-
relates with the energy of the charged particles, the refractive
index of the medium and the radioactivity of radionuclides.
We plotted the number of CL emitted per millimeter within
400–800 nm wavelength range as a function of the energy
of charged particle according to the Frank-Tamm equation
(Figure 1B). It shows that the CL production is highly depends on
the energy of particles. And according to the Frank-Tamm equa-
tion and the simulation results demonstrated by Mitchell et al.,
the CL production also relate to the index of refraction when the
energy of charged particles is lower than 0.5MeV, and the number
of CL (400–800 nm) emitted per decay positively correlate with
the energy of charged particles [4]. This means the intensity of
CL produced by one radioactive decay is reliable when a certain
isotope is used.
Beattie et al. demonstrated a series of quantitative models
with some essential corrections to experimentally observe the
CL production efficiency and distribution of some common
used radionuclides [11]. The models of CR production efficiency
were based on the Frank-Tamm equation using several different
radionuclides. They showed that the focus of the lens significantly
affects the detected sensitivity of CLI. And amore important find-
ing in this work was that the light intensity correlates with the
refractive index of the medium. This indicated that the CR should
be varieties in different tissues since the refractive index of tissues
are very different. But radionuclides emit higher energy charged
particles are less sensitive to the variation in refractive index of tis-
sues. As Ackerman et al. reported the CL production is not only
dependent on the energy of particles and the refractive index but
also on geometry. Hence, different phantoms have been used for
quantifying Cerenkov light production in vitro. They found that
Cerenkov photon productions were different between the six-well
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plate geometry, simple cubic geometry and centrifuge tube geom-
etry. For the six-well plate simulation, the surface radiance can be
considered accurate [12].
The CL intensity also correlates with the radionuclides and
radioactivity because the energy of charged particles emitted from
different radionuclides are various and the number of charged
particles increases with increasing radioactivity of radionuclides.
Liu et al. was systemically studied the CL intensity of a vari-
ety of radionuclides including β− (90Y, 131I, 111In and 177Lu),
β+(18F and 64Cu) and γ-emitters (99mTc) (Figure 1C) [13]. As a
result, the CL intensity of all tested radionuclides except for 99mTc
were highly sensitive to the radioactivity with 1–5min OI assay.
Because 99mTc is a pure γ-emitter with 141 keVγ-ray, it is hard
to produce the CL even through the secondary electrons when
the γ-ray passing through the medium. The results also showed
that the spectrum of CL in vitro consistent with the prediction
from Equation (3), and it can be seen that the CL spectrum
for different radionuclides shared a similar distribution pattern
which dependents on 1/λ2 (Figure 1D). However, the spectrum
of 18F-fluorodeoxyglucose (18F-FDG) in the heart and bladder of
mouse were obviously different with the spectrum of 18F-FDG
in vitro because the UV and blue band of CL is easily absorbed
and scattered by tissue [8].
All of the features of CR indicated that it could be devel-
oped qualitatively and quantitatively for radiopharmaceutical and
imaging studies in biology since the optical signal is correlated
with the activity of radionuclides accumulated in the tissue, the
kind of tissue and the depth of the radioactive source. But it also
should be normalized with different cameras and distance from
the lens to organs. Furthermore, the CL spectrum in different
organs is unique, and thus this special wide wavelength of emis-
sion spectrum could be used for calculate the depth of the organs
or used for CL tomography reconstruction. We will discuss about
this in later sections.
APPLICATIONS OF CR
In 1958, Pavel Alekseyevich Cerenkov shared the Physics Nobel
Prize with Ilya Frank and Igor Tamm. In his Nobel Prize lecture,
Cerenkov said that “there can be no doubt that the usefulness of
this radiation will in the future be rapidly extended” [14]. Indeed
CR has been developed and used in several important appli-
cations, such as in charged particle detectors, β radionuclide
counters, calibrators of clinical electron accelerators and espe-
cially, in biological imaging methods. And so far, many studies
have theoretically and experimentally evaluated the use of CL
with various radionuclides, as shown in Table 1. We will review
these important applications of CR in the following sections.
CERENKOV CHARGED PARTICLE DETECTOR
In the past few decades, even though interest in CR was high,
the absence of a sufficiently sensitive and convenient measur-
ing device resulted in CR mainly being used to design detectors
for counting charged particles or directly determining the veloc-
ity of charged particles. A large number of counters of this sort
were described by Jelley [7], Schaumloffel [15], and recently,
Arinc [16]. Compared with liquid scintillation methods, the
Cerenkov counter is advantageous because of the ease of sample
Table 1 | The properties of radionuclides evaluated for CR
applications.
Nuclide Application Decay
mode
Energy (keV) Half-life
18F PET β+ (97%) 633.5 109min
13N PET β+ (100%) 1198.2 9.97min
74As PET β+ (26.1%)
β− (18.6%)
944.61353 17.77 d
64Cu PET β+ (17.8%) 653 12.7 h
89Zr PET β+ (23%) 2400 78.4 h
124I PET β+ (11.7%) 1534 4.17 d
68Ga PET β+ (88%) 1899 67.6m
131I SPECT β− (89.9%) 606 8.02 d
γ (81.7%) 364
90Y Radiotherapy β− (99.9%) 2280 64h
32P Radiotherapy β− (100%) 1710 14.26 d
198Au Radiotherapy β− (98.9%) 960.7 2.69 d
111In Radiotherapy β− (100%) 448.3 2.8 d
177Lu Radiotherapy β− (78.6%) 498.3 6.73 d
225Ac Radiotherapy α (50.7%) 5830 10 d
*99mTc SPECT γ (89%) 140.5 6.01 h
*99mTc has shown to have no significant CR.
preparation, the large volume of sample and the easy recoverabil-
ity of the sample for further chemical treatment. The counting
efficiency of Cerenkov counters reach 70% of 32P disintegration,
according to a report by Parker et al. [17]. Although the counting
efficiencies of Cerenkov counters are lower than liquid scintilla-
tion methods, the use of non-coincidence circuitry, wavelength
shifters and plastic vials should increase sensitivity and may per-
mit the extension of the technique to less energetic β-emitting
nuclides [18].
According to a review by Francois in 1973, the Cerenkov
detector can be used to assay more than 15 types of β-emitting
radionuclides, including 32P, 40K, and 198Au [19]. In their review,
the relation between detection efficiency and β particle energy was
described as a logarithmic function when the maximum parti-
cle energy is 0.932–3.55MeV. Subsequent researches have been
aimed at optimizing the Cerenkov detector for increased effi-
ciency for radionuclide detection. Recently, Gunther reported
a rapid method for determining 89Sr and 90Sr in water and
milk samples using Cerenkov counters [20]. 210Pb also can be
measured by combining Cerenkov counters with the established
liquid scintillation efficiency tracing technique, according to a
report by Arinc et al. [16]. Thus, Cerenkov detector is an impor-
tant method for measuring β-emitting radionuclides, especially
for pure β-emitters.
EARLY BIOLOGICAL APPLICATIONS OF CR
Following the utility of the determination of CR by means of
β-emitters in aqueous solutions, the early use of CR in biolog-
ical samples was demonstrated by Lanchli in 1969 [21]. They
tested the kinetics of the absorption of potassium labeled with
86Rb in excised barley roots at concentrations ranging from 0.01
to 0.2mM KCl by determining the CR produced by 86Rb. They
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showed that CR could be used successfully to monitor the kinetics
of potassium absorption of plants, and inspired by this theory,
the CR could also be used to examine the metabolism behavior
of other biological materials, such as animal organs or tissues.
Two years later, Burch et al. investigated the utility of CR as a
diagnostic method to detect the light produced by 0.8mCi 32P,
which was injected intravenously (i.v.) into the medial ear vein
of an anaesthetized rabbit for eye tumor diagnosis. They found
that CR was a sensitive method for detecting and quantitating
radionuclides in tumors [22]. In another study by Smith et al.
[23], 32P diisopropyl phosphorofluoridate (DF32P, 60-240μCi)
was injected into normal and thrombocytopenic dogs via the
cephalic vein. The platelets were recovered and processed from
4.5–13.5mL of blood, and the platelet recovery was calculated by
counting the CR.
CERENKOV LUMINESCENCE IMAGING
In the absence of sufficiently sensitive and convenient imaging
devices, CR used to be detected only by a counting detector,
as described above. In recent years, advances in the OI devices
in biophotonics field have progressed rapidly with the develop-
ment of highly sensitive, charge-coupled detectors (CCD) that
can detect the weak light produced by CR to form a digital image.
This new imaging modality was then named as CLI [24].
In 2009, three groups reported the in vivo CL molecular imag-
ing of some common clinically used radionuclides such as 18F
and 13N for positron emission tomography (PET), 99mTc and 131I
for Single-photon emission computed tomography (SPECT) and
90Y for radiotherapy [8, 13, 24]. They validated the in vivo CLI
coupled with OI, PET or SPECT as multimodality imaging strat-
egy for animal imaging using 18F-FDG (Figure 2), Na18F, Na131I,
90Y-RGD-BBN, and other radio-labeled probes. An increase in
CL signal was observed with the accumulation of the radioac-
tive probes in mouse xenograft tumor. These works demonstrated
that CLI imaging highly correlate to the PET or SPECT/CT
imaging and indicated that CLI could be used to monitor the dis-
tribution of radiopharmaceuticals in vivo. As such, the term, CLI,
was coined for this new molecular imaging method.
Besides these early in vivo studies of CLI, Cho et al. described
the use of CR imaging as a method for quantitatively measure-
ment of 18F in a microfluidic chip, which is a new method for
monitoring radiochemical synthesis [25]. A lens-coupled CCD
system was used for quantitatively imaging the CL produced from
18F in a microfluidic chip. It provided a tool for investigating and
developing microfluidics for radiochemical synthesis.
Generally, this new OI modality does not require change of
the procedures or instruments of OI and does not need external
excitation. Thereafter different groups have studied on the appli-
cations of radionuclides labeled probes in CLI and have showed
very encouraging results.
CLI of positron emission radionuclides
Positron emission radionuclides, such as 18F, 15O, 13N, and 11C
labeled tracers, have been widely used for diagnosing diseases.
As mentioned, the energy of most commonly used PET radionu-
clides are higher than the threshold energy (261 keV) to produce
CL. Therefore, these radionuclides, including the most widely
used 18F and other PET radionuclides, such as 13N, 64Cu, 89Zr,
124I [26], 68Ga [8], and 74As [27] were thus studied for CLI in
different applications.
18F-FDG is the most accessible PET probe in clinic and has
been widely used for the assessment of tumor glucose metabolism
[28]. Now, performed with CLI technology, it could be detected
easily by OI [13, 24, 29]. The biodistribution of 18F-FDG was
dynamically monitored by CLI and PET/CT over the course of
time. The 18F-FDG accumulations in the brain, tumor, and kid-
neys observed with CLI was in agreement with the PET images.
The optical signal measured by CCD increased proportionally to
the radioactivity of 18F-FDG and consistent with the standard-
ized uptake value (SUV) and the percentage of injected dose per
gram (ID%/g) determined from PET at each time point. But
interestingly, the kidney/tumor ratio measured by CLI was lower
than that obtained by nuclear medicine imaging, likely due to
the limited tissue penetration ability of CL, suggesting CLI has
limitations for deep tissue imaging and quantification but has
good prospect for subcutaneous tumor imaging studies with low
interferer of other organ signal. It was also studied that the opti-
cal signal of 13N labeled probes with higher positron energy was
higher than the signal of 18F labeled probes. Consistent with the
CR theory, it also showed that the optical signal increases as the
energy and refractive index increases.
Besides using 18F-FDG-CLI for tumor imaging, recently, 18F-
FDG was used for the in vivo imaging of brown adipose tissue
(BAT), which is the tissue for thermogenesis and plays important
roles in metabolism and energy expenditure under both healthy
and disease status [30]. As such, high CLI quality was obtained
when 18F-FDG (200–300 μCi with i.v. injection) was used. It
demonstrated that CLI was ideal for BAT imaging study, because
the location of BAT is often shallow and situated away from large
organs, such as liver, heart, and stomach.
Except for 18F-FDG, other 18F labeled probes also could
be studied by CLI. Such as 18F-FHBG (9-(4-18F-fluoro-3-
[hydroxymethyl]butyl)guanine) for imaging the reporter gene-
herpes simplex virus type-1 thymidine kinase (HSV1-tk) [31],
and 2-18F-fluoro-CP-118,954 (18F labeled acetylcholinesterase
inhibitor for evaluating the reduction in AChE activity which is
very important to the patient with Alzheimer’s disease (AD) [32].
Some other positron emission radionuclides such as 124I and
89Zr were also studied with CLI by some groups. 124I is a com-
monly used PET imaging radionuclide for thyroid imaging and
89Zr is a long-lived (t1/2: 78.4 h) positron-emitting radionuclide
that is generally used for the labeling of monoclonal antibod-
ies (mAbs) for PET imaging. Jeong et al. demonstrated CLI
for thyroid gland imaging using 124I [33]. The in vitro cell
studies and in vivo imaging both indicated that the CLI of
radioactive iodine was good correlated with PET imaging. To
assess the potential application of 89Zr CLI in vivo, Ruggiero
et al. used the 89Zr-labeled mAb 89Zr-desferrioxamine B (89Zr-
DFO-J591) to detect the prostate-specific membrane antigen
(PSMA) expression of prostate cancer [26] and subsequently
reported another 89Zr labeled mAb, 89Zr-DFO-trastuzumab,
for target-specific and quantitative CLI imaging of HER2/neu-
positive tumors in vivo [34]. Recently, 89Zr CLI was also
used for quantitative non-Hodgkin’s lymphoma (NHL) imaging
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FIGURE 2 | In vivo CLI and microPET of a nude mouse bearing C6-FLuc
tumor injected with 18F-FDG. (A) Luciferase/luciferin bioluminescence
image of the tumor. (B) CLI images of the mouse injected via tail vein with
18F-FDG at 0.5, 1, 2 h. (C) MicroPET images of the mouse injected via tail vein
with 18F-FDG at 0.5, 1, 2 h. (D) CLI of the mouse after opening the thorax.
(E) CLI of the organs of the mouse. (F) Quantitative analysis of CLI results.
(G) Quantitative analysis of microPET results. (H) The correlation between
CLI signal and PET signal. (Adapted with the permission of Liu et al. [13]).
using 89Zr-desferrioxamine-rituximab in humanized huCD20
transgenic mouse models [35].
Finally, all of these studies concluded that the measured CL
signal of these positron emission radionuclides showed a positive
correlation with the radioactivity of the radionuclides, moreover,
showed a good correlation between CL signal and PET signal
in vivo. This suggesting that CLI is a potentially quantitative and
sensitive imaging method as PET for biological research, such as
metabolism imaging, tumor-target imaging, report gene imaging
and antibody imaging.
CLI of beta emission radionuclides
CR has been applied for countering β− emitter since such
radionuclides cannot be detected directly because of the low pen-
etration of the β− particles. During the development of drugs
for targeted radiotherapy, β− emitting radionuclides were shown
to have great therapeutic benefit due to the limited path length
and high linear energy transfer (LET) of the β− particles. Such
radiopharmaceuticals were promising for cancer therapy [36].
However, the biodistribution and uptake of the pure β− emitter-
labeled radiopharmaceuticals cannot be imaged directly using
conventional SPECT or PET. Thus, CLI has a great advantage for
imaging such β− radionuclides.
131I is a commonly used β− and γ emission radionuclide and
can be used for therapy and imaging of thyroid disease since
iodine ion accumulates in the thyroid [37].
131I is a good theranostic isotope, but the SPECT imaging of
it usually shows low resolution since the γ-ray energy of 131I
is too high (364KeV) for SEPCT imaging. However, combined
high-resolution OI technique, CLI shows good prospect of 131I
imaging with high resolution. In another study, CLI was used for
visualizing the expression of let-7 in lung adenocarcinoma A549
cells transfected with human sodium/iodine symporter-ras gene
(hNIS-RU) [38]. Then, 3D CLI tomography was demonstrated
to quantify tumor-associated aminopeptidase N (APN/CD13)
expression with 131I labeled Asn-Gly-Arg peptide (131I-NGR)
[39]. All of the results showed that CLI could non-invasively
detect miRNA and aminopeptidase N expression and consistent
to the SPECT imaging data. Liu et al. used Na131I for thyroid CLI,
which showed the accumulation of the 131I in thyroid as well as
showed in SPECT/CT [13]. After the in vivo CLI and SPECT/CT,
the mice were sacrificed to expose the thyroid and other organs.
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Further CLI revealed that the thyroid could be clearly differen-
tiated with high resolution. This suggests that the CLI imaging
could be used for surgery guidance, which will be discussed in
section CLI Guided Surgical Resection.
90Y and 32P both are pure β− radionuclides with long half-
life (64 h for 90Y, 14.29 days for 32P) and high β− particles
energy. They were widely used for radiotherapeutic or diagnos-
tic purposes. However, because they lack gamma photons, only
Bremsstrahlung radiation can be used in SPECT imaging for
them, but the resolution of such Bremsstrahlung SPECT imaging
is too low to be used. As such, CLI provides new strategy for such
pure β− radionuclide imaging. The CLI was successfully used for
dynamically monitoring the distribution and clearance properties
of 90Y labeled probes in tumor bearing mice [13, 40], metabolism
of 32P-phosphate in plant [41], and the spatial and temporal
distribution of 32P labeled Adenosine triphosphate (32P-ATP)
uptake in vivo [42].
Recently, Wang et al. reported that 198Au has the CR effect.
A novel 198Au-Gold Nanocages (AuNCs) were synthesized for
CLI. This radioactive nanoparticles were shown to accumulate
well in the tumor and emitted luminescence with continuous
wavelengths in the visible and near-infrared (NIR) regions for
CLI [43].
In a summery, the CLI could be used for most kind of
β− radionuclides especially for pure β− radionuclides imag-
ing in vivo. It shows great advantages of high resolution to
Bremsstrahlung SPECT imaging or high energy γ camera imag-
ing. This is very helpful for radionuclide therapy research with
high resolution and sensitivity.
CLI of alpha emission radionuclides
Recently, an alpha emission radionuclide, 225Ac, was studied for
CLI by Ruggiero et al. and was found to give very high intense
optical signal [26]. 225Ac releases α-particles with high energies
in the range of 5,021 to 5,830 keV. However, the α particles are
known to travel at velocities below the threshold for CR, although
the luminescence signal could be observed by an OI system. The
possible explanation was that the optical emissions originate from
a series of short-lived, β− emission daughter nuclides, includ-
ing 213Bi, 209Pb and 209Tl. Then, by using the simulation toolkit
Geant4, the CL output from the decay chain of 225Ac, 230U, 213Bi,
212Bi, and 212At were studied. As a result, 230U and 211At produce
little CL because of more than 10-years half-lives. 213Bi and 212Bi
produce an order of magnitude more CL than 18F, but there are
many more than 1 MeV high-energy γ-rays in the decay chains
that also produce CL. The CL produced by these high-energy
γ-rays depends on the volume of medium thus not images the
location of 213Bi and 212Bi. For 225Ac, it can be imaged by CLI
since there are β− radionuclides in its decay chain. However, these
daughter radionuclides may no longer attach to the target and
thus the CL may be delayed from the initial 225Ac decay, possi-
bly decreasing the correlation of the 225Ac labeled drug location
and light source [12].
CANCER THERAPY MONITORING
Because PET and SPECT have been approved and used for can-
cer therapy monitoring, and the same radionuclide labeled probe
used for these imaging modalities may also be used for CLI.
Xu et al. demonstrated a proof-of-concept study of monitor-
ing cancer drug therapy with CLI [44]. They used two com-
mon radiotracers, 3′-[18F]fluoro-3′-deoxythymidine (18F-FLT)
and 18F-FDG, to perform CLI and PET in therapy monitoring.
Two murine tumor models, a lung cancer cell line H460 and
prostate cancer cell line PC3 were treated with bevacizumab vs.
vehicles. Subsequently, they selected Bevacizumab as a therapeu-
tic agent to treat mice bearing H460 xenografts, and then they
performed CLI and PET to monitor the therapy effect with 18F-
FLT. Excellent correlations were found between CLI and PET for
the monitoring of cancer therapy [45]. Robertson et al. used CLI
and PET to compare the efficacy of MLN4924, a phase 2 oncol-
ogy therapeutic [46]. The CLI data correlated well with PET
and showed dynamic sensitivity. That means the CLI could be
used for tumor therapy monitoring in biology studies. This will
give big benefit for those labs without PET or SPECT imaging
instruments.
CLI GUIDED SURGICAL RESECTION
Because of its unique imaging characteristics, CLI has the poten-
tial to be used as a very efficient method for identifying small
tumor masses and defining the localization or extent of tumor
lesions with accurate delineation of tumor margins. Accordingly,
it can potentially be used to guide surgical resection. Holland
et al. demonstrated the use of CLI as a tool to guide the surgical
resection of tumors [34]. A series of CLIs was recorded before,
during, and after surgical resection of the BT-474 (HER2/neu
positive) tumor after 144 h of 89Zr-DFO-trastuzumab injections.
The optical signal intensity of the image recorded after sur-
gical incision and exposure of the tumor increased markedly.
After surgery, the complete loss of optical signal emitted from
the mouse was observed at the former location of the tumor.
Overall, these pre-, post-, and intraoperative optical images
showed the potential for using CLI as a surgical resection
guide.
Thorek et al. investigated CLI for dynamic mapping and guid-
ing surgical resection of lymph nodes (LNs) in animal models
using intradermal administration of 18F-FDG [47]. The transit
and accumulation of the 18F-FDG at the sacral nodes provided
sufficient CR to guide surgical intervention and resection of LNs.
The intradermal injection isolated the 18F-FDG to the draining
lymphatic channels and their associated LNs. The sacral node
could be seen after removal of the skin (i.e., in an intraoperative
setting), before any of them was revealed by surgical incision.
Another very important tool for surgery guidance is the use
the endoscopy, which is reviewed in the next section.
CL ENDOSCOPIC IMAGING
Endoscopy has played a significant role in the diagnosis of gas-
trointestinal diseases and surgery guidance. However, because
traditional endoscopic imaging is anatomic imaging, it is some-
times difficult to distinguish between some diseases with similar
anatomical abnormalities or the boundaries between tumor and
normal tissue. Multimodality imaging combining anatomical and
functional imaging methods has been a very important tool for
cancer diagnostic and surgery guidance. Thus, endoscopy is often
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combined with anatomical and functional imaging to achieve a
comprehensive interpretation and understanding [48].
Our group combined different optical fibers and endoscopy
with CCD to investigate whether CL can be detected with opti-
cal fibers or endoscopes [49]. We reported that the throughputs
of the optical fibers were different depending on the core diame-
ters of the optical fibers. The throughput of the optical fiber with
6mm core diameters is relatively higher compared to others used
in the study. The limiting concentration of 18F-FDG that could be
reliably detected with CL was as low as 1μCi. This allowed fiber
optics to be used for detecting the CL from the organ of inter-
est in the body. This optical fiber imaging system was then used
to detect the CL signal from different parts of C6 glioma tumor
bearing mice after intravenous injection of 18F-FDG. Consistent
with PET, optical fiber imaging found relatively high signals from
the subcutaneous tumor and brain, indicating a high uptake of
18F-FDG in these tissues. However, the image obtained from this
system only displayed as a facula because the CCD was separate
from the ocular of the optical fiber. We then improved this system
and investigated the proof-of-concept of using Cerenkov lumines-
cence endoscopy (CLE) to guide cancer surgical resection [50].
The fiber-based CLE system comprised an imaging optical fiber
coupled to a highly sensitive intensified CCD camera and showed
high spatial resolution and sensitivity. This CLE system was used
to demonstrate surgical resection guidance in a xenograft mouse
model bearing C6 glioma tumors. The study successfully provides
additional support for the use of CLI as a promising modality for
endoscopic molecular imaging.
EXTERNAL RADIOTHERAPY APPLICATIONS
A number of recent of studies have demonstrated the feasibility
of collecting CL that is excited by an external radiation beam.
As mentioned previously, the optical signal intensity increases as
the energy of the charged particles increases. The commonly used
linear accelerator works with high energy of more than 1MeV,
which is far greater than the threshold energy in water of 261 keV.
Thus, the liner electron beam might produce a stronger CL. In
some external radiotherapy beam dosimetry instruments, such
as plastic scintillators, the CL has sometimes been considered
as an unwanted background signal [51–55]. However, CL pro-
duced by charged particles, and monitoring the CL generated
in the medium can potentially be used for dosimetry measure-
ment. Jang et al. fabricated a fiber-optic CR sensor (FOCRS) for
measuring the CR produced by a therapeutic proton beam. The
CL measured increased linearly with the increasing dose rate of
the proton beam [56]. They further fabricated a plastic optical
fiber for the same purpose [57]. When a photon beam passes
through a medium, it reacts with the medium and produces
Compton electrons, which can travel at a speed higher than light
in this medium and thus produce CL. The depth dose distribu-
tion of the photon beam depends on the electron fluxes at each
depth of a water phantom because Compton scattering is the pre-
dominant interaction for the photons. Additionally, according to
the theory of the Cerenkov effect and relativity, the intensity of
CR is directly proportional to the depth doses for a therapeu-
tic photon beam. Finally, the percentage depth doses (PDD) of
the photon beam were obtained using the CR generated in plastic
optical fiber over a depth of 8mm, with only near-surface region
correction.
Glaser et al. investigated the use of projection imaging for
external radiotherapy photon beam profiling [58]. By using
Monte Carlo simulations for correction, the CLI based beam pro-
files were compared to PDD, and the reference dose distribution
was generated from the radiotherapy treatment planning system
(TPS). As a result, the optical signal intensity of CLI was directly
correlated to the deposited dose and demonstrated the CLI to pro-
file x-ray photon external radiotherapy beams in water. However,
the 2D projections of the CLI appeared blurred and yielded val-
ues higher than expected just outside the beam edge and lower
than expected values just inside the beam edge. This group also
investigated the full 3D CLI beam profiling and quality assurance
(QA) for x-ray photon beams. They explored an optical-based
dose imaging approach that allows 2D projection imaging in a fast
timeframe and created full 3D profiles after tomographic recon-
struction frommultiple projections. This approach reinforced the
importance on patient-specific treatment plans during external
radiotherapy.
Similar to β− particles, the high energy electron beam which
was commonly used for external radiotherapy, could also produce
CL according to the theory of CR. Axelsson et al. systematically
studied the CL generation by an external electron beam with dif-
ferent energies using a water-based phantom [59]. The intensity
of CL produced by an external electron beam increased along with
increasing the electron energy. The spectrum study also demon-
strated that the spectrum of CL generated by external electron
beams is similar to the CL spectrum produced by radionuclides
but contains blue-shifted light. Furthermore, the blue-dominated
spectral of CL can excite a fluorophore called protoporphyrin IX
(PpIX) which selectively accumulates in brain tumors and has
photosensitizing properties that can be used for photodynamic
therapy (PDT). Thus, external electron beams could be used to
achieve PDT due to Cerenkov effect.
Because the oxygenation of the tumor tissue plays an impor-
tant role during radiation therapy [60], Axelsson et al. mea-
sured the hemoglobin oxygen saturation (StO2) non-invasively
in tumor tissue in vivo [61]. The total hemoglobin concentration
and hemoglobin oxygen saturation could be estimated by mea-
suring the absorption and fitting the spectrum of the CL. This
methodology enables the quantitative analysis of hemoglobin
concentration and oxygen saturation and provides real-time
physiological information about the tissue during external radi-
ation therapy. Based on this work, they further demonstrated
the non-invasive and quantitative verification of the tissue StO2
and oxygen partial pressure (pO2) in vivo. The tomographic
imaging of StO2 and oxygen partial pressure (pO2) in deep
tissues was studied using Monte Carlo analysis and tissue oxy-
genation phantoms, respectively. The emission lifetime of some
oxygen-sensitive phosphorescence was directly related to the tis-
sue pO2. The CL induced by the external radiotherapy beam
could excite these probes and thus be used to measure the tis-
sue pO2. This study indicates that the StO2 and pO2 in tumor
tissue can be quantitatively measured by detecting the CL during
radiation therapy [62]. Following this approach, they investigated
the tomographic images of phosphorescence excited by CL using
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a series of phantoms with various oxygenation states [63]. The
successful pO2 distribution tomography during external radio-
therapy may significantly impact radiotherapy studies, although
this technique still needs further optimization for faster and more
sensitive acquisition.
Another use of CL in external radiotherapy was radiation dose
calibration and quality assessment. This work was reported by
Glaser et al. in 2013 [64]. They investigated a high speed and
high-resolution full 3D tomography of CL induced by external
radiotherapy beams to estimate volumetric dose distributions
in a pure water phantom. It is very important to do the dose
distribution calibration and quality assessment before external
radiation therapy because the accurate dose is needed to achieve
the desired therapy effect with minimal side effects. This non-
invasive technology was not only able to evaluate the energy
deposition of charged particles, but it also could be applied to
additional applications utilizing high-energy ionizing radiation.
INTERNAL EXCITATION SOURCE
Fluorescent imaging has been widely used for biology research. In
fluorescence imaging, the fluorophores are excited by an external
light, and thus, CL may serve as an internal source for exciting
these different fluorophores for fluorescent imaging. Liu et al.
demonstrated this concept by using quantum dots (QDs) excited
by 131I for OI [65]. Three type of CdSe/ZnS core/shell QDs
(QD655, QD705, and QD800) were selected and mixed with
Na131I for in vitro and in vivo OI studies. As a result, three flu-
orescence emission peaks at 650 nm, 705 nm and 800 nm were
observed separately, corresponding to the characteristic emis-
sions of these QDs. For the in vivo imaging studies, Na131I was
mixed with QD655, QD705, and QD800, and the resulting mix-
ture was injected subcutaneously into different locations of the
mice. Images were then obtained using different filters for each
QD’s emission and were displayed with different colors. Thus it
gives a multi-colored imaging in one time for different drugs.
Since the spectrum of CR is very wide, it not only excites the
QDs but also could excite much more fluorophores. For example,
CL internal excites radioluminescent nanophosphors (RLNPs,
Ba0.55Y0.3F2:Tb3+, and Ba0.55Y0.3F2:Eu3+) for animal fluores-
cence imaging [66]. This provided a novel CL excited fluorescence
OI method.
In another interesting study, Ran et al. demonstrated CL utility
for internal excitation and the photoactivation of luciferin 1-(4,5-
dimethoxy-2-nitrophenyl) ethyl ester (DMNP-luciferin) in vivo
[67]. In this study, 18F-FDG (0.4 mCi) was injected into the
mice bearing luciferase-expressing breast tumors before DMNP-
luciferin administration to allow the 18F-FDG to distribute to the
tumor properly. Optical images were obtained to evaluate the CL
excitation effect after injecting the DMNP-luciferin. Their results
indicate that the CL from 18F-FDG activates the DMNP-luciferin
to release the luciferin for bioluminescence imaging at signifi-
cantly higher levels even than that of with 365 nm UV activation.
This work shows the successful application of CL as an internal
excitation for photoactivation.
By using Cerenkov energy transfer theory, a targeted and
activatable fluorescent probe, which could be excited by CL,
was established to detect and quantify the activities of some
molecules, like enzyme [68]. This strategy was named secondary
Cerenkov-induced fluorescence imaging (SCIFI). In detail, the
gold nanoparticles (AuNPs) as a quencher were conjugated
to a fluorescein (FAM) with a biocompatible activatable pep-
tide linker. The linked peptide could be cleaved by matrix
metallopeptidase-2 (MMP-2) enzyme in vivo. After this activat-
able probe was injected, 18F-FDG was injected to excite the FAM.
Once the linked peptide was cleaved by MMP-2, the AuNPs will
not quench the FAM and the specific emission of FAM could
be detected and imaged with OI instrument. Thus the activity
of MMP-2 enzyme was detected according to the SCIFI emis-
sion peak. This strategy lends CLI for further investigation of
target-specific and cleavable multiple probes in vivo imaging.
Recently, Kotagiri et al. demonstrated that using DNA as a
spacer to control the distance between QD655 and 64Cu produces
the CL to excite the QDs [69]. To test the distance-dependent
CL energy transfer, QD655 and 64Cu distance was set between
1.15 nm to 31.15 nm using DNA as a linker. The luminescence
emission increased as the distance between QD655 and 64Cu
increased from 1 nm to 31 nm. Additionally, Cu2+ has a signifi-
cant quenching efficiency on QD luminescence, and thus can be
used both as a CLI probe and a luminescence quencher.
The ultraviolet (UV) light is usually used to excite the fluo-
rophores or activate the chemical reaction in some OI methods.
But it is limited by insufficient penetration of UV light in tis-
sue when it is used for in vivo imaging, and this imaging cannot
be effectively used in deep tissues. Thus, CL was considered as
a good internal excitation alternative to UV. In a word, the CLI
has great potential applications as an internal excitation source in
vivo to activate the chemical reactions, QDs, PDT drugs or other
fluorophores for different purpose.
HUMAN APPLICATION
The first human use of CLI was demonstrated for human thy-
roid imaging by Spinelli et al. [70]. They obtained the CLI images
for a patient with hyperthyroidism that was treated with 15 mCi
of 131I. The CLI was acquired using an electron multiplied CCD
(EMCCD) OI system in a light tight dark room without win-
dows and neon lamps. The patient and the room door were
covered by thick black curtains to avoid any possible external
light. After treatment with 131I for 24 h, the patient was imaged
for 2min, with the camera focusing on the head and neck region
of the patient. A significant CL signal was observed at the thy-
roid region and was confirmed by a nuclear medicine physician
with extensive experience in thyroid imaging (Figure 3). This
first human CLI demonstrated that it is possible to obtain a
planar image from the superficial organs of patients with radioac-
tive probes. This method was named Cerenkography. Recently,
another human superficial organ CLI was reported to successfully
detect the diagnostic doses 18F-FDG accumulations in axillary
LNs using sensitive optical equipment [71]. Different with the
thyroid CLI, the axillary LNs CLI was performed with a diagnos-
tic dose of radioactive probe by using a more sensitive optical
camera. This demonstrated that the CLI technique has signifi-
cant potential applications by visualizing the optical emissions
of radioactive tracers accumulated in human organs or tumors
and will be more sensitive and accurate with the development of
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FIGURE 3 | The CLI image (A) and the overlay between the
photographic image (gray color) and the CLI image (colorful) (B) of the
human thyroid. (Adapted with the permission of Liu et al. [65]).
optical instruments. There should be a further development of
CLI in human applications.
OPTIMIZATION OF CLI
The CL intensity is relatively weak and the most intensive CL
occurs in the spectrum of the UV and blue wavebands because
of the inverse square wavelength dependence. However, UV and
blue light are usually easily scattered and absorbed by biological
tissues [72]. Thus, for in vivo imaging, the penetration and scat-
tering of CL will complicate the detection and quantification of
CLI. As such, several groups have sought to optimize the CLI by
shifting the inherent emission to the NIR wavelengths that have
better penetration and lower scattering.
A high Stokes-shift QD nanoparticle, Qtracker705, which can
produce highly red-shifted photonic emissions of 705 nm by
excitation at 350 nm, was used for CR energy transfer (CRET)
imaging by Doehager et al. [73]. The absorption spectrum of
Qtracker705 overlaps the UV/blue emissions of CR, and thus,
it absorbs the CL and produces light with a peak centered
at 705 nm. They demonstrated that efficient energy transfer
could be detected with 64Cu and 18F mixed with Qtracker705
(Figure 4). The CRET ratio was calculated and normalized to
quantify the imaging signals as a quotient of the light detected
within a spectral window centered on the Qtracker705 emis-
sion divided by the light detected within a spectral window
of the CR emission. 18F-FDG CLI transferred by Qtracker705
nanoparticles showed high CRET ratios in vitro and in vivo.
Additionally, the donor intensity decreased and CRET quasi-
linear increased with increasing concentrations of Qtracker705
within the narrow concentration range. This report demon-
strates that the UV/blue CL can be absorbed and transferred
to far-red and NIR emission by the QD nanoparticles. This
result suggests that other types of energy transfers could be
potentially applied to other isotopes that produce CL in the
media.
FIGURE 4 | (A) UV/vis emission spectra of [64Cu]CuCl2 in PBS containing
various concentrations of Qtracker705 nanoparticles (Qdots), [64Cu]CuCl2
without Qdots (blue), [64Cu]CuCl2 with 49 nM (green), 222 nM (orange),
400 nM Qdots(red); non-radioactive CuCl2 without Qdots (black), with
400 nM Qdots(brown); and decayed [64Cu]CuCl2 with 400 nM Qdots (gray).
(B) In vivo CRET imaging of subcutaneous pseudotumors of 500 nM Qdots
with Matrigel (closed arrow) and PBS with Matrigel (open arrow) in
opposing flanks of nu/nu mice by using IVIS 100 with open, 510 nm (blue
band), 500–570 nm (green band), and 590 nm (red band) filters following
tail-vein injection of 18F-FDG (17.6MBq). (Adapted with the permission of
Dothager et al. [73]).
Lewis et al. reported another CL transfer study using fluo-
rophore agents as a converter [27]. In this study, some fluo-
rophores with potential preclinical applications were used, such as
europium (III) chloride hexahydrate (EuCl3), thulium (III) chlo-
ride hexahydrate (TmCl3), gadolinium (III) chloride hexahydrate
(GdCl3), indocyanine Green (ICG), and gadopentetate dimeglu-
mine. Each of these fluorophores was mixed with 14μCi of 18F
or 74As per well in a black plastic well plate, and the spectrum
was tested. The luminescence of the wells with the fluorophores
and 18F-FDG were stronger than the well with 18F-FDG alone.
The luminescence peaks of europium (III) chloride hexahydrate
excited by 18F and 74As were near 600 nm, and 700 nm, respec-
tively, which have stronger penetration in tissue. Additionally,
the luminescence peak near 600 nm of EuCl3 appeared to be
red-shifted with 74As excitation compared to 18F. A weak lumi-
nescence was also observed in a well containing only fluorophores
and surrounded by wells containing 74As. This luminescence may
attribute to the excitation by lower energy photons from 74As.
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This phenomenon observed may have potential applications in
the future.
To optimize the CLI, Spinelli et al. investigated the theoret-
ical enhancement of photon intensity in the NIR wavelength
band based on a photon propagation diffusion model [74]. Their
results showed that despite the low intensity of CL in the NIR
band, the luminescence transferred from the tissues was stronger
than that in the visible band. According to this, the CCD that was
optimized for the NIR range detection would yield a higher opti-
cal signal and thus enhance the imaging quality of CLI. By using
this optimized CCD, the enhancement was approximately 35%
and was more significant when the source was located in deeper
tissue. Overall, by using energy transfer strategy, the UV/visible
band of CL could be absorbed by some fluorophores and could
emit NIR light, which could be detected by optimized CCDsmore
effectively. However, the absorber could be further developed for
improved efficiency and a greater red shift.
In summary, the CLI quality could be significantly improved
by using some red shift fluorophores, but the energy transfer effi-
ciency still not high enough that causing the insufficient emission
at NIR window. And even the CL energy was transferred to NIR
emission, the tissue penetration of the light still limit by scatter
and absorption and thus still cannot be used in deep organ imag-
ing. Another shortage of this optimization strategy is the use of
fluorophores, which still have not been approve for clinical use
while most of the CLI probes have been used in clinical for a long
time. Once conjugated with fluorophores, the CLI probes cannot
be used in clinical study anymore. Thus, these optimize strategy
still not very ideal enough and need further optimization.
TOMOGRAPHY
As an imaging method, two-dimensional (2D) planar imaging
lacks depth information, while three-dimensional (3D) optical
tomography provides more precise spatial distribution and infor-
mation about the probes and diseases. Therefore, some studies
described the use of 3D tomography reconstruction for CLI and
named the technique CLT. Li et al. first proposed that CLT could
be used to evaluate the distribution of radioactive tracers in vivo
by surface measurement of CL [75]. The CLT was reconstructed
by using an inverse algorithm and the diffusion equation (DE)
adapted from that used for bioluminescence optical tomogra-
phy (BOT) [76]. The phantom or animal studies with radioactive
probe were placed between two mirrors inside a very sensitive OI
system. The CCD camera simultaneously captured images of the
695–770 nm narrowband CL from the top and two side surfaces
of the phantom or animal using themirrors. Then, the images was
reconstructed quantitatively by 3D tomography and compared
with PET imaging. The distribution of 18F-FDG in the animal
reconstructed by CLT was concordant with that obtained by PET.
However, the spatial resolution of CLT is much lower than PET
because of light scattering. In this method, the number of mea-
surement, photon propagation and the spectral information all
affect the image quality of the CLT. A narrower bandwidth filter,
multispectral measurements and higher sensitivity CCD help to
improve image quality in future developments of the technique.
Another reconstruction approach, multispectral diffuse CLT
(msCLT), was investigated by Spinelli et al. [77]. The msCLT
was reconstructed by a set of planar images acquired using a
series of narrowband (FWHM: 20 nm) emission filters from 560
to 660 nm. All of these planar images were reconstructed to 3D
images based on the diffusion approximation (DA) theory. By
using chicken breast and mouse muscle simulations, the reso-
lution was estimated with different depths of light sources by
msCLT and showed that the resolution was approximately 1.5mm
at 6mm depth and decreased with increasing depth. The 3D
biodistribution of 32P-ATP was obtained using msCLT and was
concordant with that obtained in MRI images. As this work
demonstrates, msCLT could improve the reconstruction quality,
but the imaging time was relatively longer because a series of
multispectral images must be obtained using a set of filters.
In contrast to homogeneous and multispectral-based meth-
ods, Hu et al. performed in vivo 3D-CLT using a heterogeneous
mouse model with an implanted Na131I radioactive source con-
sisting of a glass tube in the mouse abdomen [78]. The images
were obtained with a 695–770 nm narrowband emission filter and
were reconstructed by the hp-finite element method (hp-FEM)
based on DE. They quantitatively reconstructed the localization
and intensity of the radioactive source with a gradient concen-
tration of Na131I. The reconstructed CLT images were merged
with the micro-CT image for multimodality imaging to obtain
more information. The precision of the position reconstructed
by 3D CLT was compared with the position on the micro-CT
and SPECT images. The result showed that the reconstructed CL
intensity correlated with the radioactivity and the SPECT sig-
nal of 131I. Additionally, this 3D reconstruction method is more
accurate than the homogeneous method. For further CLT study,
they improved the CLT/CT reconstruction method and used it
to image the 131I uptake in mouse thyroid glands (Figure 5)
[79]. They investigated a more efficient, semi-quantitative hybrid
spectral CLT because it does not need a filter. The results of
both the implantation mouse model and the 131I uptake in
mouse thyroid were encouraging, with reduced acquisition and
image reconstruction time. Furthermore, the reconstructed posi-
tion and quantification of the 131I source in the phantom was
more accurate than single-spectral CLT but a little less accurate
than msCLT. This research group then presented a SPECT-guided
reconstructionmethod for CLT, in which prior information of the
permissible source region from the SPECT imaging results was
incorporated to reduce the inverse reconstruction problem [80].
The experimental results showed that the reconstruction quality
and spatial resolution were improved.
Zhong et al. investigated another CLT/CT reconstruction with
third-order simplified spherical harmonic (SP3) approximations
and whole-body tomography imaging [81, 82]. They established
the large-scale linear equations for CLT via the SP3 method
and demonstrated better imaging quality and reconstruction effi-
ciency than those from DA in biological tissues. Whole-body CLT
of small animals was successfully performed. For faster recon-
struction speed, they investigated another CLT method with
geometric row scaling and L1/2 regulation [83].
In summary, all of these multi-view or multi-spectral CLT
methods provide 3D distribution of the radioactive probe in vivo
and correlated well with PET or SPECT images. Further work is
needed to improve sensitivity and accuracy because CL is very
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FIGURE 5 | The CLT images of athymic nude mice with tail vein
injection of 450 μ Ci Na131I. (A) The 3D rendering of the Na131I
uptake in the mouse thyroid. (B) The CLT reconstruction results of
hybrid spectral CLT of Na131I uptake in the mouse thyroid in horizontal,
coronal, and sagittal views respectively. (Adapted with the permission of
Hu et al. [79]).
weak and its intensity occurs mostly in the short wavelength band,
which is easily scattered or absorbed by tissue.
LIMITATIONS OF CR
Given by the CL theory and the experiments results, the
widespread implementation of CL in various applications is still
challenging. The first issue of CL is the relatively weak optical
signal intensity, which could result in difficulties in high sensi-
tivity detection or imaging. As we described in the second section
of this review, the signal is approximately 2.4 photons per decay
for 18F. Accordingly, if 100μCi of 18F-labeled probe is injected
for an imaging study, the total optical flux is only approximately
9 × 106 photons/s. The second limitation of CL is insufficient
penetration. The CL spectrum is continuous and ranges from the
UV to NIR wavelength, and its intensity is related to wavelength
by 1/λ2. Thus, the most intensive CL is in the spectrum of the
UV/blue band, which is easily scattered and absorbed by biolog-
ical tissues. The NIR emission of CL is quite weak, though it has
higher capability to penetrate biological tissues. Therefore, only a
small portion of CL emitted from the radionuclide in vivo can be
detected by OI systems. Thirdly, most of the absorbance of light
by tissues is caused by hemoglobin in the blood. Therefore, the
organs containing more blood absorb a significant amount of CL.
Additionally, tissues with different concentrations of hemoglobin
will also have different refractive indexes. The CL intensity quan-
tity and imaging resolution decrease with increasing tissue depth.
Thus, the quantification ability of CL is relative poor especially for
deep tissues and strongly depends on the tissue type and the loca-
tion of the body. Themajor challenge for implementing CR-based
imaging and detection technique is the variety and limited pene-
trability of light into deep tissue. However, this limitation can be
minimized in small animal imaging, and CL also can be used as a
depth-independent self-generating light source.
ADVANTAGES AND POTENTIAL APPLICATIONS OF CLI
In the past a few decades, interest in CR was mainly focused on
the Cerenkov detector, which was used to monitor some radionu-
clides that do not emit gamma rays. Presently, it has been shown
to be useful in imaging the in vivo distribution of radioactive
probes, which are usually imaged by nuclear imaging modalities.
In comparison to PET and SPECT, CLI is advantageous in terms
of its low cost and high-throughput potential. As shown in some
studies, CLI has possibility to image up to five animals in less
than 5min, compared with PET scans, which require 5–20min
or longer to image one animal. Additionally, because CLI corre-
lates highly with PET studies for superficial tissues, it has been
used to quantitatively measure radiotracer uptake in vivo. With
its high throughput and resolution, CLI is beneficial for imaging
and analysis, especially for some superficial tumors or organs.
However, the application of CLI is limited by its low tissue
penetration ability, as discussed in the previous sections. This
restricts the use of CLI to small animal research or to human
superficial tissues. Some studies have demonstrated that CL could
serve as an alternative internal excitation source by using energy
transfer strategies, which opens new directions for CLI. CLI thus
can be improved through excitation fluorophores to produce NIR
light, which is more suitable for in vivo OI, or it could be com-
bined with PDT to increase the efficacy of treatments. As reported
by several studies, some photosensitizers for PDT need to be
excited by UV or blue light, which almost match the CL spectrum
[84, 85]. Therefore, CL could be used to excite such molecules for
PDT, especially when combined with therapeutic radionuclides.
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This strategy may supply potential clinical benefits not only for
superficial tumors but also for deep tumors. Additionally, the
high-energy X-rays or electrons used for radiotherapy can also
induce CL, which could be used for activating photosensitizers
for PDT. This type of strategy would combine radiotherapy and
PDT, and it may also monitor the radiation dose accumulation
by CLI.
CONCLUSION
The CR provides a simple, quantitative tool for radionu-
clide detection, CLI, radiotherapy monitoring, endoscopy, and
optical-guided surgery and for the excitation of fluorophores or
other photosensitizers. With further development, it may benefit
researchers by serving as a novel multi-functional tool for biology
research.
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